Lansoprazol Ranbaxy

Lansoprazole, the active ingredient in Lansoprazol Ranbaxy, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is indicated for conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazol Ranbaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

- Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief by reducing esophageal acid exposure. - Peptic ulcer disease: promotes ulcer healing by lowering gastric acidity. - Erosive esophagitis: facilitates mucosal recovery through sustained acid suppression. - Helicobacter pylori eradication regimen: used as part of combination therapy to improve eradication rates.

Lansoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild headache reported in clinical use. - Diarrhea: loose stools occurring during therapy. - Nausea: transient nausea without vomiting. - Abdominal pain: mild discomfort in the upper abdomen.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis reported with prolonged use. - Hypomagnesemia: low blood magnesium levels that may cause muscle cramps or arrhythmia. - Stevens‑Johnson syndrome: rare severe skin reaction requiring immediate medical attention.

Before initiating therapy, consider the following precautions. - Assess renal function: adjust use in severe renal impairment. - Monitor magnesium levels: prolonged therapy may deplete magnesium. - Avoid abrupt discontinuation: may cause rebound acid hypersecretion. - Use with caution in elderly: higher risk of fractures. - Pregnancy and lactation: evaluate risk‑benefit with prescriber. - Store at room temperature: keep in original container, protect from moisture and heat.

Lansoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption of atazanavir. - Methotrexate: increased toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR. - Digoxin: possible increased serum levels. - Diazepam: may increase plasma concentration.